- Conditions
- Growth Hormone Deficiency
- Interventions
- LUM-201, rhGH Norditropin® pen (34 µg/kg)
- Drug
- Lead sponsor
- Lumos Pharma
- Industry
- Eligibility
- 3 Years to 12 Years
- Enrollment
- 104 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2024
- U.S. locations
- 27
- States / cities
- Sacramento, California • San Diego, California • Greenwood Village, Colorado + 24 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–5
of 5
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- NAFLD, Nonalcoholic Fatty Liver, NASH - Nonalcoholic Steatohepatitis
- Interventions
- LUM-201
- Drug
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 21 Years to 60 Years
- Enrollment
- 12 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2024
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Growth Hormone Deficiency
- Interventions
- LUM-201
- Drug
- Lead sponsor
- Lumos Pharma
- Industry
- Eligibility
- 3 Years to 13 Years
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2025
- U.S. locations
- 7
- States / cities
- San Diego, California • Washington D.C., District of Columbia • Indianapolis, Indiana + 4 more
- Conditions
- Growth Hormone Deficiency
- Interventions
- LUM-201
- Drug
- Lead sponsor
- Lumos Pharma
- Industry
- Eligibility
- 5 Years to 14 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2028
- U.S. locations
- 6
- States / cities
- Iowa City, Iowa • Worcester, Massachusetts • Kansas City, Missouri + 3 more
- Conditions
- Growth Hormone Deficiency (GHD)
- Interventions
- LUM-201, Matched Placebo (Capsules)
- Drug · Other
- Lead sponsor
- Lumos Pharma
- Industry
- Eligibility
- 3 Years to 11 Years
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 29
- States / cities
- Birmingham, Alabama • Madera, California • Orange, California + 26 more